Welcome to our dedicated page for Fibrogen SEC filings (Ticker: FGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings archive for FibroGen, Inc. (FGEN) provides regulatory documents that trace the company’s evolution into Kyntra Bio, Inc. A Form 8-K filed in January 2026 reports a Certificate of Amendment to the Amended and Restated Certificate of Incorporation, changing the company’s name from FibroGen, Inc. to Kyntra Bio, Inc. The same filing notes that the company’s common stock, formerly trading under the symbol FGEN, began trading on Nasdaq under the symbol KYNB on January 8, 2026, with the CUSIP number unchanged.
Other Form 8-K filings in this archive document key corporate events and financial updates. These include reports on quarterly financial results, amendments to financing agreements, and the completion of the sale of FibroGen International (Hong Kong) Ltd. (FibroGen China) to AstraZeneca Treasury Limited. The filings describe the total consideration for that transaction, the inclusion of all roxadustat assets in China, and the subsequent repayment of a senior secured term loan.
Investors can use these filings to understand how the company presents its business, capital structure, and strategic transactions to regulators. While detailed annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transaction reports (such as Form 4) are not listed in the provided data, the available 8-Ks illustrate how FibroGen, now Kyntra Bio, communicates material events, including regulatory approvals related to the China divestiture and financial condition updates.
On Stock Titan, these historical FGEN filings are paired with AI-powered tools that help interpret complex disclosures, highlight significant items in event-driven reports, and connect corporate actions—such as the name change, asset sale, and financing amendments—to the broader narrative of the company’s transformation into Kyntra Bio.
FibroGen, Inc. completed the sale of all issued and outstanding equity interests of its subsidiary FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited on August 29, 2025 for approximately $220 million, closing a previously announced transaction under a Share Purchase Agreement dated February 20, 2025. The deal represents a disposition of assets associated with FibroGen’s China anemia business structure. The company also provided unaudited pro forma condensed consolidated financial information, including a balance sheet as of June 30, 2025 and statements of operations for the year ended December 31, 2024, in Exhibit 99.1 to help illustrate the financial impact of this divestiture.
FibroGen, Inc. reported that it has completed the sale of FibroGen International (Hong Kong) Ltd., including its FibroGen China operations, to AstraZeneca Treasury Limited for total consideration of approximately $220 million. This amount consists of $85 million in enterprise value and about $135 million in net cash held in China, with $6.0 million held back for final cash adjustments and $4.0 million held back for potential indemnity claims.
FibroGen and a subsidiary sold all equity interests in the Hong Kong entity and its China roxadustat assets to AstraZeneca, which has long partnered with FibroGen on roxadustat in greater China and South Korea. FibroGen keeps roxadustat rights in the United States, Canada, Mexico, and other territories not held by AstraZeneca or licensed to Astellas Pharma Inc. At closing, FibroGen repaid its term loan facility with investment funds managed by Morgan Stanley Tactical Value for approximately $81 million.
FibroGen, Inc. announced that Chinese regulators approved the proposed sale of FibroGen International (Hong Kong) Ltd. and its subsidiaries (“FibroGen China”) to AstraZeneca Treasury Limited under a share purchase agreement dated February 20, 2025.
The China State Administration for Market Regulation decided not to prohibit AstraZeneca’s acquisition of FibroGen China, which includes all of FibroGen’s roxadustat assets in China. The transaction is subject to customary closing conditions and deliverables and is expected to close in the third quarter of 2025.
FibroGen and its subsidiary FibroGen China Anemia Holdings, Ltd. will sell all issued and outstanding equity interests of FibroGen International (Hong Kong) Ltd. to AstraZeneca, FibroGen’s long-time commercialization partner for roxadustat in greater China and South Korea. FibroGen will retain rights to roxadustat in the United States, Canada, Mexico, and in markets not already held by AstraZeneca or licensed to Astellas Pharma Inc. in Europe, Japan, and certain other territories.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 336,000 shares of FibroGen, Inc. common stock, representing 8.31% of the outstanding class based on the issuer's reported share count in its most recent 10-Q. Armistice Capital acts as investment manager to the Master Fund, the direct holder of the shares, and exercises shared voting and dispositive power over the reported securities. Mr. Boyd, as managing member of Armistice Capital, is similarly reported to have shared voting and dispositive power. The Master Fund disclaims direct beneficial ownership due to the investment management arrangement.
FibroGen, Inc. reported condensed consolidated results for the quarter ended June 30, 2025. Total assets were $178.1 million versus $214.5 million at year-end 2024, and the company reported a consolidated total deficit of $202.5 million. For continuing operations, total revenue was $1.35 million for the quarter and $4.09 million for the six months ended June 30, 2025. The company recorded a net loss of $7.6 million for the quarter and $3.0 million for the six-month period; income from discontinued operations was $6.08 million for the quarter and $27.49 million for six months.
The company entered a share purchase agreement to sell FibroGen International to AstraZeneca for $85 million plus the net cash in China, with closing expected in the third quarter of 2025 subject to China SAMR approval. Management disclosed substantial doubt about the company’s ability to continue as a going concern without closing the sale or obtaining additional financing and must satisfy a U.S. cash covenant of $18.75 million. The company has a $75 million senior secured term loan (principal) that is presented as current with maturity in May 2026 and a liability related to the sale of future revenues of approximately $63.0 million.
FibroGen, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025; the press release is included as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104.
The company states the press release is furnished (not deemed "filed") for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other SEC filings. This 8-K does not include numerical financial results within the filing text; investors should review Exhibit 99.1 for the detailed figures and disclosures.